King Luther Capital Management Corp Buys 13,300 Shares of Bristol Myers Squibb Company $BMY

King Luther Capital Management Corp increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 2.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 531,286 shares of the biopharmaceutical company’s stock after purchasing an additional 13,300 shares during the period. King Luther Capital Management Corp’s holdings in Bristol Myers Squibb were worth $28,658,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. waypoint wealth counsel bought a new position in Bristol Myers Squibb in the fourth quarter valued at about $1,194,000. Life Cycle Investment Partners Ltd bought a new position in Bristol Myers Squibb in the fourth quarter valued at about $34,406,000. Axxcess Wealth Management LLC grew its position in Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after acquiring an additional 21,196 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Bristol Myers Squibb by 4.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211,845 shares of the biopharmaceutical company’s stock valued at $99,754,000 after acquiring an additional 93,528 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in Bristol Myers Squibb by 6.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 531,538 shares of the biopharmaceutical company’s stock valued at $23,972,000 after acquiring an additional 32,005 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $57.63 on Thursday. The business’s 50-day moving average price is $58.42 and its 200-day moving average price is $56.18. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The firm has a market capitalization of $117.68 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 0.17 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the firm posted $1.80 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.31 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Cantor Fitzgerald lifted their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, April 8th. Barclays assumed coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price on the stock. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price on the stock. Guggenheim reiterated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Finally, HSBC lifted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $61.31.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.